Rankings
▼
Calendar
COLL Q1 2025 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
$1B
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$178M
+22.7% YoY
Gross Profit
$97M
54.8% margin
Operating Income
$22M
12.2% margin
Net Income
$2M
1.4% margin
EPS (Diluted)
$0.07
QoQ Revenue Growth
-2.3%
Cash Flow
Operating Cash Flow
$55M
Free Cash Flow
$55M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$1.4B
Stockholders' Equity
$234M
Cash & Equivalents
$96M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$178M
$145M
+22.7%
Gross Profit
$97M
$91M
+6.4%
Operating Income
$22M
$49M
-56.2%
Net Income
$2M
$28M
-91.3%
Revenue Segments
Belbuca
$52M
35%
Xtampza ER
$48M
32%
Nucynta IR
$27M
18%
Nucynta ER
$20M
13%
Symproic
$3M
2%
← FY 2025
All Quarters
Q2 2025 →